Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results

被引：0
|
作者：
Izzo, F.
Catino, A. M.
Vogl, T. J.
Middleton, M.
Valle, J. W.
Fiore, F.
Gadaleta, C. D.
Pirotta, R. M.
Martignoni, M.
Laffranchi, B.
机构：
[1] NCI, Fdn G Pascale, Naples, Italy
[2] IRCCS Osped Oncol, Bari, Italy
[3] Hosp Johann Wolfgang Goethe Univ, Frankfurt, Germany
[4] Univ Oxford, Churchill Hosp, Oxford, England
[5] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[6] Nerviano Med Sci, Nerviano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4593
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Temozolomide (TMZ) and cisplatin (CDDP) combination in naive patients with stage IV melanoma. Definitive results of a phase II multicenter trial
    Tourani, J.
    Wiersbicka, E.
    Mourey, L.
    Guillot, B.
    Sassolas, B.
    Bedane, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] EFFICACY AND TOLERABILITY OF BEVACIZUMAB (B) AND ERLOTINIB (E) AS FIRST-LINE THERAPY IN ASIAN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A PHASE II TRIAL
    Hsu, C.
    Kang, Y.
    Yang, T. S.
    Su, W.
    Shun, C.
    Sandoval-Tan, J.
    Chiou, T.
    Jin, K.
    Hsu, C.
    Cheng, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 237 - 237
  • [23] A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
    He, Aiwu Ruth
    Kim, Alexander Y.
    Toskich, Beau M.
    Mody, Kabir
    Kim, Kevin
    Stein, Stacey
    Goyal, Lipika
    Abrams, Thomas Adam
    Brown, Daniel
    Goff, Laura Williams
    Kim, Richard D.
    Parikh, Nainesh
    Sandow, Tyler
    Johnson, Daniel
    Iyer, Renuka V.
    Petroziello, Michael
    Krishnamurthi, Smitha S.
    Martin, Charles
    Jiang Yixing
    Akhter, Nabeel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [24] Phase II trial of SOM230 in patients with unresectable hepatocellular carcinoma (HCC).
    Feun, Lynn G.
    Savaraj, Niramol
    Wangpaichitr, Medhi
    Richman, Stephen P.
    Kwon, Deukwoo
    Dinh, Vy
    Martin, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring
    Malka, D.
    Dromain, C.
    Farace, F.
    Horn, S.
    Pignon, J.
    Ducreux, M.
    Boige, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A phase II trial of docetaxel and cisplatin combination in patients with locally advanced undifferentiated carcinoma of the nasopharynx: Updated results
    Farugui, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 152 - 152
  • [27] IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC).
    Vogel, Arndt
    Waidmann, Oliver
    Muller, Tobias
    Siegler, Gabriele Margareta
    Goetze, Thorsten Oliver
    De Toni, Enrico N.
    Gonzalez-Carmona, Maria A.
    Hausner, Guido
    Geissler, Michael
    von Weikersthal, Ludwig Fischer
    Kestler, Angelika M. R.
    Finkelmeier, Fabian
    Kleiss, Matthias
    Marquardt, Jens U.
    Teufel, Andreas
    Klagges, Jorge
    Eickhoff, Regina
    Al-Batran, Salah-Eddin
    Saborowski, Anna Lena
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 555 - 555
  • [28] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
  • [29] A phase II, randomized, controlled trial of nivolumab in combination with BMS-986253 or cabiralizumab in advanced hepatocellular carcinoma (HCC) patients
    Welling, Theodore
    Beri, Nina
    Siolas, Despina
    Cohen, Deirdre Jill
    Becker, Daniel Jacob
    Zhong, Hua
    Wu, Jennifer J.
    Oberstein, Paul Eliezer
    Karasic, Thomas Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC)
    Knox, Jennifer J.
    Qin, Rui
    Strosberg, Jonathan R.
    Kaubisch, Andreas
    El-Khoueiry, Anthony B.
    Bekaii-Saab, Tanios B.
    Erlichman, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345